{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:30:51Z","timestamp":1757608251206,"version":"3.44.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020869","name":"AstraZeneca Kabushiki Kaisha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.lungcan.2024.108027","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T06:16:43Z","timestamp":1731565003000},"page":"108027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study"],"prefix":"10.1016","volume":"199","author":[{"given":"Hidehito","family":"Horinouchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Atagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kozuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Tokito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Oizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Mio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Iwane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Koto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2024.108027_b0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/JTO.0b013e318219aae2","article-title":"Japanese Lung Cancer Registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade","volume":"6","author":"Sawabata","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0010","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/JTO.0b013e31824c945b","article-title":"Surgical outcome of stage IIIA- cN2\/pN2 non-small-cell lung cancer patients in Japanese Lung Cancer Registry study in 2004","volume":"7","author":"Yoshino","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejcts.2009.04.013","article-title":"Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival","volume":"36","author":"Decaluw\u00e9","year":"2009","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2024.108027_b0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.athoracsur.2014.04.067","article-title":"Management of clinical stage IIIA primary lung cancers in the National Cancer Database","volume":"98","author":"Hancock","year":"2014","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2024.108027_b0025","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jtho.2016.09.135","article-title":"Role of postoperative radiotherapy in pathologic stage IIIA (N2) non-small cell lung cancer in a prospective nationwide oncology outcomes database","volume":"12","author":"Herskovic","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijrobp.2015.09.026","article-title":"Candidates for intensive local treatment in cIIIA-N2 non-small cell lung cancer: deciphering the heterogeneity","volume":"94","author":"Horinouchi","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2024.108027_b0035","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jtcvs.2003.09.012","article-title":"Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe","volume":"127","author":"Inoue","year":"2004","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2024.108027_b0040","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/JTO.0b013e31828f68b4","article-title":"Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer","volume":"8","author":"Koshy","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0045","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/JTO.0000000000000152","article-title":"National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer","volume":"9","author":"Patel","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jtcvs.2010.07.092","article-title":"Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors","volume":"141","author":"Paul","year":"2011","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2024.108027_b0055","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.108027_b0060","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2014.58.5380","article-title":"Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base","volume":"33","author":"Robinson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0065","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3747\/co.26.4549","article-title":"Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review","volume":"26","author":"Swaminath","year":"2019","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0070","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jnci\/djk093","article-title":"Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer","volume":"99","author":"van Meerbeeck","year":"2007","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.lungcan.2024.108027_b0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2018.02.008","article-title":"Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)","volume":"118","author":"Cou\u00f1ago","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.108027_b0080","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ejcts\/ezu504","article-title":"Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer","volume":"48","author":"Darling","year":"2015","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2024.108027_b0085","first-page":"845","article-title":"Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review","volume":"9","author":"Xu","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.lungcan.2024.108027_b0090","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00159-2019","article-title":"International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?","volume":"6","author":"Putora","year":"2020","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.lungcan.2024.108027_b0095","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.108027_b0100","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.108027_b0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable Stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0110","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.108027_b0115","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.108027_b0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lungcan.2021.12.005","article-title":"Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study","volume":"165","author":"Murakami","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.108027_b0125","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1002\/cam4.3306","article-title":"Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study","volume":"9","author":"Horinouchi","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2024.108027_b0130","unstructured":"Ministry of Health, Labour and Welfare, Ethical Guidelines for Medical and Health Research Involving Human Subjects (provisional English translation, March 2015). Amended February 28, 2017. Available at: https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka\/0000080278.pdf. Accessed: November 25, 2024."},{"year":"2010","series-title":"AJCC Cancer Staging Manual","key":"10.1016\/j.lungcan.2024.108027_b0135"},{"key":"10.1016\/j.lungcan.2024.108027_b0140","unstructured":"Japan Lung Cancer Society, General Rule for Clinical and Pathological Record of Lung Cancer, eighth ed., Kanehara, Tokyo, Japan, 2017."},{"key":"10.1016\/j.lungcan.2024.108027_b0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral Stage IA non-small-cell lung cancer","volume":"388","author":"Altorki","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.108027_b0150","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","author":"Saji","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.108027_b0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtcvs.2020.09.146","article-title":"A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer","volume":"163","author":"Suzuki","year":"2022","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2024.108027_b0160","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(12)70139-0","article-title":"Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)","volume":"13","author":"Atagi","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13646-z","article-title":"Prediction of treatment response for combined chemo- and radiation therapy for non-small cell lung cancer patients using a bio-mathematical model","volume":"7","author":"Geng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2024.108027_b0170","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2009.24.7577","article-title":"Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007","volume":"28","author":"Segawa","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0175","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1200\/JCO.2009.24.5050","article-title":"Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2017.11.014","article-title":"Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy","volume":"115","author":"Isaka","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.108027_b0185","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00595-015-1268-2","article-title":"Outcomes of initial surgery in patients with clinical N2 non-small cell lung cancer who met 4 specific criteria","volume":"46","author":"Maniwa","year":"2016","journal-title":"Surg. Today"},{"key":"10.1016\/j.lungcan.2024.108027_b0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2023.01.008","article-title":"Reaching multidisciplinary consensus on the management of non-bulky\/non-infiltrative stage IIIA N2 non-small cell lung cancer","volume":"177","author":"Scherpereel","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.108027_b0195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS","volume":"31","author":"Park","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0200","unstructured":"Japan Lung Cancer Society, Clinical Guideline for the Management of Lung Cancer, 2022. Available from: https:\/\/www.haigan.gr.jp\/publication\/guideline\/examination\/2022\/. Accessed: November 25, 2024 (in Japanese)."},{"key":"10.1016\/j.lungcan.2024.108027_b0205","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1245\/s10434-018-6747-4","article-title":"A little bit of cancer is still cancer: is it time for lymph node micrometastases in non-small cell lung cancer to get their due?","volume":"25","author":"Arndt","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0210","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.21037\/jtd.2019.05.36","article-title":"Incidence and clinical relevance of non-small cell lung cancer lymph node micro-metastasis detected by staging endobronchial ultrasound-guided transbronchial needle aspiration","volume":"11","author":"Belanger","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2024.108027_b0215","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1245\/s10434-018-6743-8","article-title":"Lymph node micrometastasis prognosticates survival for patients with stage 1 bronchogenic adenocarcinoma","volume":"25","author":"Ren","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0220","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jtho.2019.04.016","article-title":"Prognostic impact of the number of metastatic lymph nodes on the Eighth Edition of the TNM Classification of NSCLC","volume":"14","author":"Katsumata","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0225","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.21037\/jtd-21-390","article-title":"Anatomical location and number of metastatic lymph nodes for prognosis of non-small cell lung cancer","volume":"13","author":"Samejima","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2024.108027_b0230","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.cllc.2015.04.004","article-title":"Prognostic significance of the number of metastatic pN2 lymph nodes in stage IIIA-N2 non-small-cell lung cancer after curative resection","volume":"16","author":"Yoo","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.108027_b0235","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1378\/chest.07-1852","article-title":"Extranodal extension in metastatic non-small cell lung cancer","volume":"132","author":"Bell","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2024.108027_b0240","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1378\/chest.06-1810","article-title":"Significance of extranodal extension of regional lymph nodes in surgically resected non-small cell lung cancer","volume":"131","author":"Lee","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2024.108027_b0245","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.3390\/jcm10153324","article-title":"Prognostic significance of the extranodal extension of regional lymph nodes in stage III-N2 non-small-cell lung cancer after curative resection","volume":"10","author":"Shih","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2024.108027_b0250","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.lungcan.2024.108027_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2022.100867","article-title":"Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities","volume":"46","author":"Bailey","year":"2022","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.lungcan.2024.108027_b0260","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.108027_b0265","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT005","article-title":"Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC","volume":"83","author":"Heymach","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2024.108027_b0270","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0275","article-title":"The impact of the availability of immunotherapy on patterns of care in Stage III NSCLC: a Dutch multicenter analysis","volume":"2","author":"Ronden","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2024.108027_b0280","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2217\/fon-2021-1417","article-title":"Real-world treatment patterns in resectable (stages I\u2013III) non-small-cell lung cancer: a systematic literature review","volume":"18","author":"Waser","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2024.108027_b0285","unstructured":"WCLC attendees hear preview of proposed changes for the 9th edition of the TNM staging classification for thoracic cancers. Press release, October 10, 2023. Available from: https:\/\/www.ilcn.org\/wclc-attendees-hear-preview-of-proposed-changes-for-the-9th-edition-of-the-tnm-staging-classification-for-thoracic-cancers\/. Accessed: November 25, 2024."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:52:58Z","timestamp":1756860778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224005610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":57,"alternative-id":["S0169500224005610"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.108027","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.108027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108027"}}